Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | NMBR | P28336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3336721 | 0.99 | ROCK2 (0.39) | ROCK2MGLLSIRT2ESR1ESR2 | |
| SCHEMBL3337996 | 0.90 | CTSK (0.39) | ROCK2MGLLESR1ESR2POLB | |
| Hydrochloric Acid SCHEMBL3340086 | 0.89 | CTSK (0.39) | ROCK2MGLLESR1ESR2POLB | |
| SCHEMBL27786110 | 0.88 | MAPT (0.47) | S1PR4POLBMAPTITGA4ITGB7 | |
| SCHEMBL3335362 | 0.87 | ROCK2 (0.40) | ROCK2MGLLESR1ESR2MAPT | |
| SCHEMBL2059178 | 0.87 | SIRT2 (0.48) | SIRT2MAPTL3MBTL1ITGA4ITGB7 | |
| SCHEMBL6447871 | 0.87 | SIRT2 (0.48) | SIRT2MAPTL3MBTL1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL3625843 | 0.86 | ROCK2 (0.39) | ROCK2MGLLESR1ESR2MAPT | |
| Hydrochloric Acid SCHEMBL3335270 | 0.86 | ROCK2 (0.39) | ROCK2MGLLESR1ESR2MAPT | |
| Hydrochloric Acid SCHEMBL6506712 | 0.86 | SIRT2 (0.48) | SIRT2MAPTL3MBTL1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202227-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-8324261-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2202227-A1 | NOVEL HISTIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | HRH4, HNMT, HRH3 | ROCK2 4133/4885MGLL 3945/4885SIRT2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.